ARTICLE | Company News
Kolltan, AstraZeneca deal
August 5, 2013 7:00 AM UTC
Kolltan received exclusive rights to a mAb against epidermal growth factor receptor 3 ( EGFR3; HER3; ErbB3) from AstraZeneca's MedImmune LLC subsidiary. Kolltan plans to begin Phase I testing of t...